AVEXIS INC. news, videos and press releases
For more news please use our advanced search feature.
AVEXIS INC. - More news...
AVEXIS INC. - More news...
- SAVSU Technologies to Supply evo® Cold Chain Technologies to AveXis
- AveXis Reports First Quarter 2018 Financial and Operating Results
- AveXis Provides Update on Proposed Acquisition by Novartis AG
- AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
- AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
- RM LAW Announces Investigation of AveXis, Inc.
- AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology
- WEISSLAW LLP Investigates AveXis Inc. Acquisition
- AveXis Enters Agreement to be Acquired by Novartis AG for $8.7 billion
- AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1
- AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
- AveXis, Inc. to Host Earnings Call
- AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results
- AveXis Reports Third Quarter 2017 Financial and Operating Results
- AveXis to Report Third Quarter 2017 Financial and Operating Results
- AveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle Society
- AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial Process
- AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- AveXis Announces Pricing of Public Offering of Common Stock
- AveXis Announces Proposed Public Offering of Common Stock
- AveXis Announces Alignment with FDA on GMP Commercial Manufacturing Process for AVXS-101
- AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
- AveXis Reports First Quarter 2017 Financial and Operating Results
- AveXis to Report First Quarter 2017 Financial and Operating Results
- AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
- AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Meeting of the American Academy of Neurology
- AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results
- AveXis to Report Topline Phase 1 Trial Results in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results on March 16, 2017
- AveXis to Present Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at AAN Annual Meeting
- AveXis Appoints Rick Modi as Senior Vice President and Chief Business Officer